Fig. 3: Inhaled delivery of PRS-220 achieves high, dose-dependent lung exposure with low systemic bioavailability in vivo. | Nature Communications

Fig. 3: Inhaled delivery of PRS-220 achieves high, dose-dependent lung exposure with low systemic bioavailability in vivo.

From: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment

Fig. 3

a Scheme outlining the design of a study to investigate the PK profile of daily (QD) inhaled PRS-220 in lung tissue and serum of healthy rats. Rats were treated daily with PRS-220 at 3 different dose levels by nose-only inhalation for 4 days. Created in BioRender. Pavlidou, M. (2025) https://BioRender.com/e13e683b Serum and lung exposure of free, non-target bound PRS-220 was determined over time after daily treatment with 3 different dose levels by nose-only inhalation for 4 days. Graph shows PRS-220 levels above the detection limit as mean ± SD of n = 6 animals (3 male and 3 female) per timepoint in serum and lung tissue. Figure legend indicates the mean achieved delivered dose levels during the study. c Scheme outlining the design of a study to investigate the PK profile of a single intravenous (i.v.) administration of PRS-220 in lung tissue and serum of healthy rats. Created in BioRender. Pavlidou, M. (2025) https://BioRender.com/z18p244d PRS-220 levels upon single intravenous administration at a dose level of 2 mg/kg were assessed in lung tissue and serum. Graph shows PRS-220 levels above the detection limit as mean ± SD of n = 6 animals (3 male and 3 female) per timepoint in serum and lung tissue. Source data are provided as a Source Data file.

Back to article page